Sanofi Pasteur is poised to produce the first validation batches of their dengue vaccine at the company’s state-of-the-art production centre near Lyon, France. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/sanofi_starts_dengue_vaccine_production_for_2015_launch_1005375In less than six years, GlaxoSmithKline has moved from being “virtually nowhere” in biopharmaceuticals to becoming a player in this increasingly important area of drug development. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/gsk_banks_on_becoming_big_force_in_biopharma_981382A raft of new results plus an update on ongoing clinical trials featuring Eisai’s epilepsy portfolio have been presented at the European Congress on Epileptology held this week in London. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/eisai_up_for_challenge_to_claim_epilepsy_top_spot_976505Eisai’s ambitious plans for leadership of the European epilepsy market were unveiled this week at the opening of a new production facility at the company’s £100 million EMEA research and commercial headquarters in Hatfield, UK. - News -
by Ian Mason
www.pharmatimes.com/news/eisai_eyes_eu_epilepsy_dominance_976574A tiny pain-free jab every two weeks could be the future of cholesterol-lowering for high-risk patients, according to clinical researchers gathered in Amsterdam for the European Society of Cardiology congress. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/antibody_lipid_treatments_enter_final_furlong_1005620There was good and bad news for analgesia-focused pharmaceutical companies at the European Pain Federation (EFIC) Congress, which was held in Florence. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/pain_education_and_treatment_mixed_in_europe_1005840The International Iberian Nanotechnology Laboratory was formally opened in Braga, Portugal at the weekend and the massive complex – which covers 26,000 square metres and will house 200 scientists – is scouting for pharma and biotech partners for
by Ian Mason
www.pharmatimes.com/news/portugalspains_nanotech_lab_seeks_pharma_partners_983999New data supporting the safety and long-term efficacy of Eisai’s Zonegran when used as adjunctive therapy in adolescents and children aged six years and above, with partial (focal) epilepsy have been presented at the European Paediatric Neurology
by Ian Mason
www.pharmatimes.com/news/eisais_zonegran_nudges_towards_paediatric_launch_1005756Patients in many countries are being denied effective new biologic therapies for psoriasis due to old fashioned clinical thinking and needlessly complex prescribing and reimbursement restrictions, say leading dermatologists. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/call_for_shake-up_of_biologic_regulations_for_psoriasis_987563Italy’s Dompé has unveiled ambitious expansion plans, with chief executive Eugenio Aringhieri telling PharmaTimes that its rhNGF (recombinant human nerve growth factor) will be the springboard that will transform the company. - News -
by Ian Mason
www.pharmatimes.com/news/dompe_eyes_ophthalmology_market_to_drive_growth_1002464
